Andere Sprachen Immix Biopharma, Inc.

Aktien

A3C9EJ

US45258H1068

IMMX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 19.04.2024			% 5 Tage	% 1. Jan.
2,19 ^USD	-0,90 %		-20,65 %	-68,35 %

29.03.	Immix Biopharma, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
20.03.	Immix Biopharma, Inc. gibt großes umfassendes Krebszentrum als federführenden Standort für klinische Studie zu NXC-201 Al-Amyloidose bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	18.04.
Immix Biopharma on Track to Dose NXC-201 Patients in United States	18.04.
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy	16.04.
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	15.04.
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial	20.03.
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial	20.03.
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial	20.03.
Immix Biopharma Announces 'Be Proactive in AL' AL Amyloidosis Awareness Initiative	06.03.
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative	05.03.
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative	05.03.
Immix Biopharma 12 Month Review Progress Update	21.02.
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock	08.02.
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock	08.02.
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis	07.02.
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis	07.02.
Immix Biopharma Prices $15 Million Stock Offering	06.02.
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock	06.02.
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock	06.02.
Immix Biopharma Proposes Stock Offering; Shares Slump	05.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immix Biopharma, Inc.

Aktien

A3C9EJ

US45258H1068

IMMX

Andere Sprachen

Filter